Epilepsy & Seizures

Filter Your Results




Results From Cannabidiol Dose-Ranging Safety Trial for Treating Patients With Dravet Syndrome

Wednesday, March 14, 2018—Previous randomized controlled trials have suggested that orally administered cannabidiol (CBD) is effective as an add-on to existing antiepileptic drugs (AEDs) for the treatm…

Pediatricians, Pediatric Neurologists, Patient Advocates, and Industry Partner to Create High-Tech Risk-Screening Tool for Children with Epilepsy

Tuesday, February 13, 2018—Digital Health Solutions (DHS), the Child Neurology Foundation (CNF), and Greenwich Biosciences began a collaborative effort to develop a digital tool that will prompt provide…

Food and Drug Administration Grants Breakthrough Therapy Designation for ZX008 for Treatment of Dravet Syndrome

Tuesday, February 06, 2018—Low-dose fenfluramine (ZX008, Zogenix) is classified as an orphan drug for the treatment of two rare forms of epilepsy: Dravet syndrome and Lennox-Gastaut syndrome. Positive r…

Oral Vimpat Approved for Use in Pediatric Patients with Partial-Onset Seizures

Tuesday, November 07, 2017—The FDA approved a label extension for Vimpat (lacosamide, UCB) CV as an oral option for the treatment of partial-onset seizures (POS) in pediatric patients four years an…

Next-Generation VNS System and Implantable Device Approved

Monday, October 09, 2017—LivaNova has received FDA approval for its next-generation Vagus Nerve Stimulation (VNS) Therapy Programming System for drug-resistant epilepsy. The FDA has also approved the …

Investigational Low-Dose Fenfluramine Shows Promise in Phase 3 Trial for Dravet Syndrome

Friday, September 29, 2017—Phase 3 findings suggest that the investigational ZX008 (low-dose fenfluramine hydrochloride, Zogenix) is effective for the treatment of Dravet syndrome. The study enrolled 11…

Briviact Approved as Monotherapy for Partial-Onset Seizures

Friday, September 15, 2017—The FDA has approved a supplemental new drug application for Briviact (brivaracetam, UCB) CV as monotherapy for partial-onset (focal) seizures (POS) in patients 16 y…

Aptiom Approved for Partial-Onset Seizures in Patients Four Years of Age and Older

Thursday, September 14, 2017—The FDA has approved the supplemental New Drug Application (sNDA) to expand the indication for Aptiom (eslicarbazepine acetate, Sunovion) to include treatment of partial-…


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.